THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [9.2] ID: TIP-MED-000166

Budesonide

Active Ingredient / Scientific Identity: Budesonide • Class: Inhaled Corticosteroid (ICS); Potent Topical Airway Anti-Inflammatory ('Preventer / Controller')

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Budesonide ([9.2] | ID: TIP-MED-000166) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/9-2-budesonide/
Generic / Entity NameBudesonide ([9.2])
Verified Indian Brands / RefLevolin (Cipla)
Pharmacological ClassInhaled Corticosteroid (ICS); Potent Topical Airway Anti-Inflammatory ('Preventer / Contro
Available Dosage FormspMDI Inhaler: 100 mcg, 200 mcg/puff; Rotacaps (DPI): 100 mcg, 200 mcg, 400 mcg; Nebuliser Respules (Suspension
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No dose adjustment needed. Hepatic: First-pass clearance is impaired in severe liver cirrhosis, increasing systemic st
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Budesonide (TIP-MED-000166, Reference Code [9.2]) is classified under Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Inhaled Corticosteroid (ICS); Potent Topical Airway Anti-Inflammatory ('Preventer / Controller'). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Levolin (Cipla)
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.2], p. 114): Budecort (Cipla—Inhaler, Rotacaps, Respules), Pulmicort (AstraZeneca), Derinide (Zydus); In FDC with Formoterol: Foracort, Symbicort, Budamate — Strengths & Dosage Forms: pMDI Inhaler: 100 mcg, 200 mcg/puff; Rotacaps (DPI): 100 mcg, 200 mcg, 400 mcg; Nebuliser Respules (Suspension): 0.5 mg (500 mcg) / 2 mL, 1 mg (1000 mcg) / 2 mL; Nasal Spray (Budenase AQ): 64 mcg, 100 mcg/spray; Oral Gastro-Resistant Capsules (Budesonide MMX/Entocort for IBD): 3 mg, 9 mg
Dosage Forms & Available Strengths:
pMDI Inhaler: 100 mcg, 200 mcg/puff; Rotacaps (DPI): 100 mcg, 200 mcg, 400 mcg; Nebuliser Respules (Suspension): 0.5 mg (500 mcg) / 2 mL, 1 mg (1000 mcg) / 2 mL; Nasal Spray (Budenase AQ): 64 mcg, 100 mcg/spray; Oral Gastro-Resistant Capsules (Budesonide MMX/Entocort for IBD): 3 mg, 9 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Inhaled Corticosteroid (ICS); Potent Topical Airway Anti-Inflammatory ('Preventer / Controller') acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Inhaled Corticosteroid (ICS); Potent Topical Airway Anti-Inflammatory ('Preventer / Controller') for Long-term maintenance anti-inflammatory controller therapy for Bronchial Asthma; severe COPD with frequent exacerbations and eosinophilia (combined with LABA/LAMA); acute croup and severe asthma/COPD exacerbations (Nebuliser Respules); allergic rhinitis (Nasal spray); Crohn's disease / ulcerative colitis / microscopic colitis (oral 3 mg EC capsules)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Long-term maintenance anti-inflammatory controller therapy for Bronchial Asthma
  • severe COPD with frequent exacerbations and eosinophilia (combined with LABA/LAMA)
  • acute croup and severe asthma/COPD exacerbations (Nebuliser Respules)
  • allergic rhinitis (Nasal spray)
  • Crohn's disease / ulcerative colitis / microscopic colitis (oral 3 mg EC capsules)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Inhaled Asthma Maintenance: 200 mcg to 400 mcg twice daily (up to 800 mcg BD in severe asthma). Nebulised Respules: 0.5 mg to 1 mg twice daily. Follow physician prescription.

Administration & Meal Timing: Inhaled: Independent of food (convenient to use right before brushing teeth morning and night so mouth rinsing is never forgotten!). | Twice daily (every 12 hours: morning and night).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No dose adjustment needed. Hepatic: First-pass clearance is impaired in severe liver cirrhosis, increasing systemic steroid availability—monitor for systemic steroid effects.
Elimination & Renal Adjustment:
Renal: No dose adjustment needed. Hepatic: First-pass clearance is impaired in severe liver cirrhosis, increasing systemic steroid availability—monitor for systemic steroid effects.
Hepatic Impairment Considerations:
Renal: No dose adjustment needed. Hepatic: First-pass clearance is impaired in severe liver cirrhosis, increasing systemic steroid availability—monitor for systemic steroid effects.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • NOT for rapid relief of acute bronchospasm! Caution in patients with active or quiescent Pulmonary Tuberculosis (inhaled steroids can reactivate latent TB or predispose to non-tuberculous mycobacterial/fungal pneumonia in severe COPD) and untreated oral/systemic fungal infections.

Key Clinical Precautions: Renal: No dose adjustment needed. Hepatic: First-pass clearance is impaired in severe liver cirrhosis, increasing systemic steroid availability—monitor for systemic steroid effects.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Oropharyngeal Candidiasis (Oral Thrush—creamy white painful plaques on tongue and palate, 5–10% if mouth is not rinsed!), dysphonia / hoarseness of voice (reversible steroid myopathy of vocal cords), throat irritation, reflex cough during inhalation.
  • Increased risk of Pneumonia in elderly COPD patients, adrenal suppression, cataracts, glaucoma, skin bruising, and decreased bone mineral density (primarily with prolonged high doses >800–1600 mcg/day), paradoxical bronchospasm.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Metabolised extensively on first pass (90%) by hepatic CYP3A4: Potent CYP3A4 inhibitors (Itraconazole, Ketoconazole, Voriconazole, Posaconazole, Clarithromycin, Ritonavir) block hepatic inactivation of swallowed budesonide, increasing systemic steroid exposure 4-fold and causing iatrogenic Cushing's syndrome and adrenal suppression!

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: MANDATORY 'RINSE, GARGLE & SPIT' RULE AFTER EVERY DOSE: 1. Instruct every patient using Budecort (or Foracort/Seroflo): 'Immediately after inhaling your puff or rotacap, take a mouthful of water, swish around the mouth, gargle deep in the throat, and SPIT IT OUT (do not swallow the rinse water!).' This single step prevents 90% of oral thrush and hoarse voice! 2. Using a Spacer with the pMDI further cuts throat deposition by 70%. 3. After nebulising Budecort Respules with a face mask, wash the facial skin around the nose and mouth with water (to prevent perioral steroid dermatitis) and rinse the mouth!
  • Meal & Clock Timing Instruction: Inhaled: Independent of food (convenient to use right before brushing teeth morning and night so mouth rinsing is never forgotten!). (Twice daily (every 12 hours: morning and night).)
  • Missed Dose Protocol: Inhale as soon as remembered unless close to the next scheduled dose; never double.
  • Geriatric Dispensing Pearl: Verify that elderly patients do not stop Budecort when their breathing feels normal, and always recommend a Spacer with pMDI and strict mouth rinsing + spitting.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: pMDI Inhaler: 100 mcg, 200 mcg/puff; Rotacaps (DPI): 100 mcg, 200 mcg, 400 mcg; Nebuliser Respules (Suspension): 0.5 mg (500 mcg) / 2 mL, 1 mg (1000 mcg) / 2 mL; Nasal Spray (Budenase AQ): 64 mcg, 100 mcg/spray; Oral Gastro-Resistant Capsules (Budesonide MMX/Entocort for IBD): 3 mg, 9 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.2] (p. 114)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/9-2-budesonide/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.